Shares of Gilead Sciences (GILD.US) climbed more than 5% on Wednesday, reaching $155.54 and setting a new all-time high. The company's latest financial report revealed full-year 2025 revenue of $29.443 billion, a 2.4% increase compared to the previous year. Net profit attributable to the listed company surged to $8.51 billion, representing a staggering increase of approximately 16.73 times year-over-year. Non-GAAP diluted earnings per share were $8.15, a substantial 77% rise from the prior year. Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences, stated that the past year was highly productive for the company. He highlighted the successful launch of Yeztugo, the world's first twice-yearly HIV prevention therapy, alongside the continued growth of Biktarvy and Descovy, which have established a solid foundation for the company's growth.